Corifact Approval History
FDA Approved: Yes (First approved February 17, 2011)
Brand name: Corifact
Generic name: factor XIII concentrate (human)
Company: CSL Behring LLC
Treatment for: Factor XIII Deficiency
Corifact (factor XIII concentrate (human)) is a is a fibrin-stabilizing factor concentrate indicated to prevent bleeding in people with congenital Factor XIII deficiency.
Development History and FDA Approval Process for Corifact
|Feb 17, 2011||FDA Approves Corifact to Prevent Bleeding in People With Rare Genetic Defect|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.